We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Pharmacy Practice, K. K. College of Pharmacy, Gerugambakkam, Tamil Nadu.
This article provides an in-depth overview of heart failure (HF) and the recently approved SGLT2 inhibitor, sotagliflozin, emphasizing its efficacy in treating adults with HF, type 2 diabetes, chronic kidney disease, and cardiovascular risk factors. The SOLOIST study is discussed, demonstrating the significant reduction in cardiovascular fatalities, hospitalizations, and urgent visits for heart failure with sotagliflozin use. The mechanism of action of SGLT2 inhibitors in HF, chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) is explored, highlighting their direct renal effects, indirect benefits, and cardiovascular advantages. The article concludes by emphasizing the multifaceted benefits of SGLT2 inhibition beyond glycemic control, including weight reduction, blood pressure management, and cardiovascular risk reduction. It advocates for SGLT2 inhibitors as the preferred therapy for patients with both T2DM and HF, suggesting potential expansion to all HF patients, irrespective of glycemic status, pending ongoing trials. Overall, the article underscores the pivotal role of SGLT2 inhibitors in improving clinical outcomes and longevity in individuals with HF and related comorbidities.
M. Madhumitha*, J. Ashwini, S. Nivetha, The Role Of SGLT Inhibitors In Heart Failure Beyond Glycemic Control: A Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 12, 659-669.https://doi.org/10.5281/zenodo.10427940
10.5281/zenodo.10427940